Compare FJET & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FJET | PROF |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.2M | 247.5M |
| IPO Year | N/A | 2017 |
| Metric | FJET | PROF |
|---|---|---|
| Price | $4.47 | $7.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.7M | 61.0K |
| Earning Date | 04-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | $39.74 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $4.11 | $3.92 |
| 52 Week High | $28.56 | $8.95 |
| Indicator | FJET | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 62.97 |
| Support Level | $4.49 | $6.43 |
| Resistance Level | $5.88 | $7.94 |
| Average True Range (ATR) | 0.51 | 0.34 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 25.32 | 67.30 |
Starfighters Space Inc is a commercial aerospace company based at NASA's Kennedy Space Center in Florida, with an additional base of operations at Midland International Air & Space Port in Texas, and has a fleet of seven F-104 Fighter jets that are capable of flying MACH 2+. Its activities include air launch operations, pilot and space flight training, support research, hypersonic testing, and other aerospace development programs. The company has one operating segment, which is principally the operations of F-104 Fighter jets and the development of infrastructure for orbital space launch.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.